Vyndamax (Tafamidis) for Amyloidosis

Overview
Vyndamax is approved by the U.S. Food and Drug Administration (FDA) for the treatment of cardiomyopathy (heart muscle disease) caused by wild-type or hereditary transthyretin-mediated amyloidosis. This treatment is designed to reduce cardiovascular mortality (death due to heart disease) and hospitalization related to cardiovascular issues. Vyndamax is also known by its drug name, tafamidis.

Tafamidis is a selective transthyretin stabilizer, which means it helps prevent the transthyretin protein from breaking apart and forming amyloid deposits in the heart. These deposits are believed to damage heart tissue and impair heart function.

How do I take it?
Prescribing information states that Vyndamax is taken orally as a capsule and is typically taken once daily. The medication should be taken exactly as prescribed by a health care provider.

Side effects
The FDA-approved label for Vyndamax lists no reported common side effects.

Rare but serious side effects may include potential harm to a developing fetus if taken during pregnancy. It is recommended that individuals who are pregnant or may become pregnant avoid this medication. Breastfeeding is also not advised while taking Vyndamax.

For more information about this treatment, visit:

Label: Vyndaqel — Tafamidis Meglumine Capsule, Liquid Filled; Vyndamax — Tafamidis Capsule, Liquid Filled — DailyMed